Mitchell J. Blutt M.D. is Director at QUESTCOR PHARMACEUTICALS INC (QCOR). They have made 14 open-market trades across 4 companies since 2006, most recently 2020-12-01.
CIK 0001097955
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
8 open-market purchases totalling $5.2M since 2006, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CHFW | SELL | 2020-11-18 | 2021-05-19 | $0.01 | $300 | N/A | N/A | N/A |
| VCEL | SELL | 2016-03-28 | 2016-03-29 | $5.39 | $647K | -45.7% | -47.4% | -64.2% |
| QCOR | SELL · 10b5-1 | 2012-09-04 | 2012-09-06 | $47.60 | $1.2M | N/A | N/A | N/A |
| QCOR | SELL · 10b5-1 | 2012-07-02 | 2012-07-05 | $53.11 | $3.7M | N/A | N/A | N/A |
| QCOR | SELL | 2012-05-04 | 2012-05-07 | $42.69 | $494K | N/A | N/A | N/A |
| QCOR | SELL | 2012-05-03 | 2012-05-04 | $43.95 | $3.5M | N/A | N/A | N/A |
| QCOR | SELL | 2011-11-15 | 2011-11-16 | $43.94 | $6.6M | N/A | N/A | N/A |
| QCOR | SELL | 2011-09-12 | 2011-09-14 | $26.13 | $9.7M | N/A | N/A | N/A |
| QCOR | BUY | 2011-03-07 | 2011-03-09 | $13.04 | $2.9M | N/A | N/A | N/A |
| QCOR | SELL · Routine | 2011-02-28 | 2011-03-01 | $12.83 | $1.4M | N/A | N/A | N/A |
| DJO | BUY | 2007-05-11 | 2007-05-15 | $34.93 | $105K | N/A | N/A | N/A |
| DJO | BUY | 2007-03-12 | 2007-03-14 | $38.00 | $247K | N/A | N/A | N/A |
| DJO | BUY | 2007-03-02 | 2007-03-05 | $37.73 | $245K | N/A | N/A | N/A |
| DJO | BUY | 2006-12-14 | 2006-12-18 | $43.29 | $822K | N/A | N/A | N/A |
| DJO | BUY | 2006-11-28 | 2006-11-30 | $43.00 | $258K | N/A | N/A | N/A |
| DJO | BUY | 2006-06-09 | 2006-06-13 | $36.92 | $362K | N/A | N/A | N/A |
| DJO | BUY | 2006-05-08 | 2006-05-10 | $42.40 | $254K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.